X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with TIMKEN INDIA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs TIMKEN INDIA - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

TIMKEN INDIA 
   Change

Tata Timken Ltd. (TTL), the country`s second largest ball-bearing (tapered and cartridge tapered) manufacturer after SKF, has become an 80% subsidiary of the $2.4 billion family controlled Timken USA, after buying out the Tata`s 40% stake in the comp... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES TIMKEN INDIA INDOCO REMEDIES/
TIMKEN INDIA
 
P/E (TTM) x 36.8 40.9 90.0% View Chart
P/BV x 2.9 5.9 48.5% View Chart
Dividend Yield % 0.8 0.2 481.6%  

Financials

 INDOCO REMEDIES   TIMKEN INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
TIMKEN INDIA
Mar-18
INDOCO REMEDIES/
TIMKEN INDIA
5-Yr Chart
Click to enlarge
High Rs3601,008 35.8%   
Low Rs249630 39.5%   
Sales per share (Unadj.) Rs119.0181.5 65.6%  
Earnings per share (Unadj.) Rs8.413.5 61.8%  
Cash flow per share (Unadj.) Rs15.219.9 76.6%  
Dividends per share (Unadj.) Rs1.601.00 160.0%  
Dividend yield (eoy) %0.50.1 430.0%  
Book value per share (Unadj.) Rs70.7103.3 68.5%  
Shares outstanding (eoy) m92.1568.00 135.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.5 56.7%   
Avg P/E ratio x36.460.5 60.2%  
P/CF ratio (eoy) x20.041.2 48.5%  
Price / Book Value ratio x4.37.9 54.4%  
Dividend payout %19.17.4 258.8%   
Avg Mkt Cap Rs m28,08355,692 50.4%   
No. of employees `0006.00.8 741.5%   
Total wages/salary Rs m2,167905 239.4%   
Avg. sales/employee Rs Th1,817.015,159.8 12.0%   
Avg. wages/employee Rs Th359.01,111.8 32.3%   
Avg. net profit/employee Rs Th127.71,130.1 11.3%   
INCOME DATA
Net Sales Rs m10,96812,340 88.9%  
Other income Rs m40208 19.0%   
Total revenues Rs m11,00712,549 87.7%   
Gross profit Rs m1,5651,633 95.8%  
Depreciation Rs m633431 146.7%   
Interest Rs m6212 509.0%   
Profit before tax Rs m9091,398 65.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139478 29.0%   
Profit after tax Rs m771920 83.8%  
Gross profit margin %14.313.2 107.8%  
Effective tax rate %15.334.2 44.6%   
Net profit margin %7.07.5 94.3%  
BALANCE SHEET DATA
Current assets Rs m5,7256,480 88.3%   
Current liabilities Rs m5,4542,489 219.2%   
Net working cap to sales %2.532.3 7.6%  
Current ratio x1.02.6 40.3%  
Inventory Days Days6273 85.7%  
Debtors Days Days7266 108.7%  
Net fixed assets Rs m5,3073,049 174.1%   
Share capital Rs m184680 27.1%   
"Free" reserves Rs m6,3316,343 99.8%   
Net worth Rs m6,5167,023 92.8%   
Long term debt Rs m1,3230-   
Total assets Rs m11,9709,789 122.3%  
Interest coverage x15.6115.5 13.5%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.91.3 72.7%   
Return on assets %7.09.5 73.1%  
Return on equity %11.813.1 90.3%  
Return on capital %12.420.1 61.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5073,467 130.0%   
Fx outflow Rs m1,1413,348 34.1%   
Net fx Rs m3,366119 2,828.2%   
CASH FLOW
From Operations Rs m886390 227.3%  
From Investments Rs m-1,706-638 267.2%  
From Financial Activity Rs m1,316-19 -6,924.7%  
Net Cashflow Rs m497-270 -183.7%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 12.5 5.5 227.3%  
FIIs % 6.0 6.4 93.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 13.2 169.7%  
Shareholders   12,805 49,890 25.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   COMPACT DISC  CREST VENTURES  TIL LTD  NALWA SONS INV  STC INDIA  



Related Views on News

TIMKEN INDIA Announces Quarterly Results (1QFY19); Net Profit Up 44.3% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, TIMKEN INDIA has posted a net profit of Rs 316 m (up 44.3% YoY). Sales on the other hand came in at Rs 4 bn (up 20.7% YoY). Read on for a complete analysis of TIMKEN INDIA's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 25, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - IL&FS INV. MANAGERS COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS